Dayli Partners

Founded in 2018, Dayli Partners is a venture capital firm based in Seoul, South Korea. It focuses on investing in bio ventures across various healthcare areas such as therapeutics, life sciences, medical devices, diagnostics, and fintech.

Seungho Lee

CEO

In-Ho Kwon Ph.D

Executive Managing Director

Yong-Chul Kim Ph.D

Managing Director

93 past transactions

Aldavar

Series A in 2024
ALDAVER provides incredibly realistic personalized surgical training models using innovative biopolymer materials that closely resemble human tissues and 3D printing technology.

Daan Biotherapeutics

Series A in 2024
DAAN Biotherapeutics is a biopharmaceutical company focused on developing innovative treatments for cancer patients. The company specializes in research and development in the field of cancer therapies, employing a range of approaches such as cell therapies, antibodies, and small molecule inhibitors. DAAN Biotherapeutics is particularly dedicated to immune-oncology, utilizing anticancer immune cell therapies, including natural killer (NK) cells and T cell receptors. Through its independent research infrastructure, the company conducts clinical trials to explore various treatment strategies, aiming to create effective new drugs, particularly for lung cancer. By providing healthcare providers with advanced therapeutic options, DAAN Biotherapeutics seeks to improve outcomes for cancer patients.

Kanaph Therapeutics

Series C in 2023
Kanaph Therapeutics is a biotechnology company focused on developing next-generation therapeutics for oncology and autoimmune diseases. Founded in 2019 and headquartered in Seoul, South Korea, the company engages in drug development activities ranging from discovery to early-stage clinical trials. Its therapeutic platform includes bi-specific antibodies, Fc-fusions, and small molecules. In oncology, Kanaph Therapeutics develops drugs with enhanced immuno-stimulatory activity in the tumor microenvironment for efficient tumor eradication. For autoimmune diseases, the company's pipeline features bispecific Fc-fusions that inhibit the alternative complement pathway, angiogenesis, and downstream complement activation. The company serves both Korea and the United States.

Medipixel

Series B in 2023
Medipixel, Inc. is a South Korean MedTech startup founded in 2017, specializing in artificial intelligence-based diagnostic software and semi-autonomous robotic systems for lung cancer and cardiac interventions. The company is comprised of a team of AI experts in computer vision, deep learning, and reinforcement learning, collaborating with top healthcare professionals, including those at Seoul Asan Medical Center, to enhance disease diagnosis and surgical procedures. Medipixel offers three primary solutions for intervention surgeons: an AI-based diagnosis tool that assists in identifying lesions during coronary angiography, a guide and planning solution that visualizes coronary arteries to facilitate guidewire manipulation, and an automated navigation engine that directs robotic units through arteries with real-time commands. These innovations aim to improve surgical outcomes and patient safety by reducing reliance on contrast agents and enhancing the precision of interventions.

Cellemedy

Series A in 2023
Cellemedy is a biotechnology company focused on developing next-generation therapeutic proteins to advance treatment options beyond traditional antibody therapies. Its proprietary platform aims to enhance antigen binding and broaden applicability across multiple medical indications. The company pursues cancer immunotherapy and immuno-oncology through research and development, including cancer cell-related therapeutics and smart nano-medicine approaches, with the goal of improving patient outcomes. By combining innovative biopharmaceuticals with targeted immune therapies, Cellemedy seeks to address unmet medical needs and contribute to healthier outcomes for patients suffering from cancer and other diseases.

CURAUM

Series B in 2023
Founded in 2017, CURAUM specializes in developing and selling oral care and sleep-related healthcare products. Its key offerings include Clium Cleaner for dental device cleaning, Clium S-Guard for managing obstructive sleep apnea and snoring, and the Clium System for personalized chronic sleeping disorder management.

Arum Therapeutics

Series A in 2023
Arum Therapeutics is a biopharmaceutical company focused on discovering and developing innovative therapeutics for cancer. It specializes in novel anticancer agents designed to overcome drug resistance, targeting DNA damage response mechanisms.

Illimis Therapeutics

Venture Round in 2023
Illimis Therapeutics is a platform-based biotechnology company developing fusion protein therapeutics for neurodegenerative and other hard-to-treat diseases. Its approach centers on a chimeric fusion protein platform that uses proprietary engineering and molecular design to advance drug candidates with improved target specificity and stability.

Generate great Experiance

Venture Round in 2023
Generate great Experiance is an IT company that develops IoT equipment for medical platform.

Phantomics

Series A in 2023
Phantomics is an artificial intelligence company focused on the development of software for the analysis and diagnosis of cardiac MRIs. The company aims to enhance diagnostic accuracy through the use of biomarkers derived from medical images. Its technology enables comprehensive analysis of these images and biomarkers, facilitating quantitative and precise disease diagnosis and prognosis prediction. By providing tools that simplify the interpretation of complex medical data, Phantomics supports medical professionals in making informed clinical decisions, ultimately improving patient outcomes in cardiac care.

Protium Science

Venture Round in 2023
Protium Science is a drug research and development company in the biopharmaceutical sector that provides analytical and quality assurance services, while also developing drug substances and finished drugs, conducting chemistry, manufacturing and controls work across production cell line development to support the creation of custom medicines and enable patients to access tailor-made therapies.

Gencellmed

Series A in 2023
Gencellmed is a biotechnology company focused on developing innovative cancer treatments using its proprietary platform technology for creating oncolytic viruses. The company specializes in engineering next-generation herpes simplex virus type 1 (oHSV-1) based therapies that selectively infect and destroy cancer cells while stimulating the body's immune response against tumors. Gencellmed aims to provide novel, effective treatment options for patients with unmet clinical needs in oncology.

K-Cell

Series A in 2023
K-Cell is a biotechnology company that offers cell storage services.

Nuvilab

Series A in 2022
Nuvilab is a company that focuses on transforming the food industry through innovative technology aimed at enhancing environmental sustainability and personal well-being. Its core product, the Nuvilab AI Food Scanner, employs advanced instant food recognition technology to accurately identify food types and volumes. By leveraging big data, Nuvilab integrates various food-related information, including details about leftovers, user preferences, and optimized menu recommendations. This comprehensive approach allows the company to provide users with personalized nutritional reports and guidelines, promoting healthier dietary habits. Through its solutions, Nuvilab aims to facilitate a more informed and sustainable approach to food consumption.

HMC Networks

Series B in 2022
HMC Networks Co., Ltd. is a South Korean company established in 2013, based in Seoul, that specializes in providing management, consulting, and investment services tailored for hospitals and clinics. The company operates CareNation, a caregiver matching platform designed to connect caregivers, guardians, and patients, leveraging extensive industry expertise. Additionally, HMC Networks has divisions focused on medical devices, food products, and personal and joint care services. By utilizing big data, HMC Networks aims to drive service innovation and address information imbalances within the medical sector.

Mxt Biotech

Series A in 2022
Mxt Biotech is a biotechnology company developing microfluidic platforms for cell engineering and immunotherapies. The company focuses on non-viral intracellular delivery, offering automated microfluidic-based systems to introduce genes and nucleic acids into cells, enabling gene editing and the advancement of cell therapies. Its technology supports scalable, controlled delivery processes to enhance cell viability and therapeutic efficacy, with applications in research and clinical development of immune and other cell-based therapies.

Cellaputics Bio

Series A in 2022
Cellaputics Bio is a biotechnology company that develops cell therapy for treating degenerative and intractable diseases.

Y-Biologics

Venture Round in 2022
Y-Biologics Inc. is a biotechnology company based in Daejeon, South Korea, specializing in the discovery and development of novel antibody therapeutics, particularly in the field of immuno-oncology. Established in 2007, the company has developed a bispecific antibody platform technology known as AliCE, which maintains the structural integrity of the parental antibody, ensuring high binding affinity to cancer antigens. Additionally, Y-Biologics has created the Y-max ABL, a unique library of human antibodies, which supports its research and development efforts. The company is recognized for its contributions to the global immuno-chemotherapeutic drug market and also offers contract research services, aiming to advance its position within the biotechnology sector.

DeepCardio

Series A in 2022
DeepCardio is a company focused on developing artificial intelligence technology to enhance the diagnosis of heart movements. It specializes in creating systems that accurately diagnose paroxysmal atrial fibrillation, a type of irregular heartbeat. By employing advanced deep learning techniques, DeepCardio enables healthcare professionals to predict arrhythmias even in patients who are not currently experiencing symptoms. This innovative approach aims to improve patient outcomes through more timely and accurate diagnoses, thereby addressing a critical need in cardiovascular health management.

SeaWith

Series A in 2022
SeaWith is a biotechnology company creating meat alternatives from seaweed, including cell-cultured steak and plant-based substitutes designed to mimic meat texture and flavor. It develops its own culture media from microalgae, aiming to reduce production costs by leveraging the abundance of algae. The company focuses on nutrition and sustainability, providing healthier protein options for consumers seeking alternatives to traditional meat.

iN Therapeutics

Series B in 2022
iN Therapeutics is a biotechnology company focused on developing novel therapies for patients with intractable neurological disorders. Its drug development platform concentrates on Nav1.7 non-narcotic analgesics, hearing loss treatments, and brain disease therapeutics, aiming to provide pharmaceutical and biotech industries access to innovative central nervous system disease drugs.

Kynogen

Series A in 2022
Kynogen is a biotechnology company focused on developing anticancer therapies aimed at improving treatment outcomes for cancer patients. The company specializes in immunotherapy and cancer metabolic drugs, allowing healthcare professionals to target various types of cancer effectively. Kynogen's approach enables the integration of its therapies with existing anticancer treatments, enhancing their efficacy while significantly reducing costs. Through its innovative solutions, Kynogen aims to contribute to the advancement of cancer care and improve the quality of life for patients battling this disease.

Space F

Series A in 2022
Space F is an application industry platform business company that researches and develops cell farming technology.

Opticho

Series A in 2022
Opticho is a company that develops ultrasound microscopes intended to enhance preclinical and clinical research. It specializes in the commercialization of these advanced imaging devices, which combine ultrasound diagnostics with laser technology. Utilizing optical principles and photoacoustic effects, Opticho's microscopes effectively visualize blood vessels, particularly peripheral ones. This innovative approach aids researchers in diagnosing peripheral vascular diseases, thereby contributing significantly to medical research and diagnostic capabilities.

Ubix Therapeutics

Series B in 2022
Ubix Therapeutics, Inc. is a research and development company based in Seoul, South Korea, focused on the development of anti-cancer drugs utilizing a proprietary proteolysis targeting chimera platform. The company employs advanced inhibitor technology that degrades specific target proteins within cells, aiming to enhance therapeutic efficacy for various cancers. By binding to proteins associated with disease, Ubix Therapeutics seeks to provide life-saving medications for patients, thereby supporting both patients and medical professionals in the fight against cancer.

Galux

Venture Round in 2022
Galux specializes in molecular design technology for discovering and developing novel drugs targeting incurable and rare diseases. Its AI-based platform integrates artificial intelligence, physics, and chemistry to design biomolecules, aiding healthcare professionals.

LYNK Solutec

Seed Round in 2022
LYNK Solutec is a laboratory-based developer of biomedical devices focused on coatings and accessories that enhance safety and efficiency in clinical settings. The company develops nano-oil film coatings designed to prevent the adhesion of blood, viruses, and bacteria, and creates medical devices such as an anti-fog and anti-blood endoscope cap to maintain the endoscope’s field of view; its activities center on research and development to address practical challenges in medical care and support safer, faster patient treatment.

LaSemilla

Seed Round in 2022
LaSemilla is an ag-tech company dedicated to mitigating global food insecurity exacerbated by climate change. It offers a sustainable food production platform and develops crops resilient to climate change through advanced biotechnology, enhancing food security via technological innovation.

GI Cell

Series B in 2022
GI Cell is a biotechnology company focused on the development of immune cell-based therapeutics aimed at addressing complex diseases. Utilizing innovative platform technology, the company specializes in screening and optimizing ancillary proteins for targeted immune cells, which are essential in treating conditions such as cancer and inflammatory disorders. Additionally, GI Cell is involved in the creation of multi-valent sub-unit vaccines for COVID-19, leveraging its expertise in ancillary protein engineering and deep understanding of immunology. This approach enables medical practitioners to provide effective treatments for patients facing challenging health issues.

Anterogen

Post in 2022
Anterogen is a bio-venture company focused on the research and development of cell therapy products and orphan drugs utilizing adult stem cells. The company has developed several products, including Cupistem injection, Queen cell, Remodulin injection, and TheraStem-Derma. In addition to its product offerings, Anterogen provides cell banking services and analytical services, which encompass sample analysis for clinical studies. Through its innovative approach, Anterogen aims to advance therapeutic options in the field of regenerative medicine.

CasCure Therapeutics

Seed Round in 2022
CasCure Therapeutics develops personalized cancer therapies by integrating artificial intelligence, deep learning, and genome-editing technologies to power pipeline devices for precision medicines and anti-cancer drugs. The company designs platforms that enable the development and optimization of targeted cancer treatments, with the aim of equipping clinicians with tools to tailor therapies to individual tumors and patient profiles. Through AI driven analysis alongside genome editing approaches, CasCure Therapeutics seeks to advance its pipeline products, including precision cancer medicines and anti-cancer agents, supporting medical professionals in delivering more effective, personalized oncology care.

Tcino Bioscience

Venture Round in 2022
Tcino Bioscience develops molecule anti-cancer drugs for cancer patients.

Mthera Pharma

Series B in 2021
Mthera Pharma is a biopharmaceutical research and development company focused on creating innovative therapies for complex diseases. The company is working on a pre-clinical drug that aims to enhance the translation of cutting-edge scientific discoveries into effective precision medicine. Mthera Pharma's lead compounds are designed to address multiple targets, enabling healthcare professionals to better manage conditions such as Parkinson's disease and dementia. Through its dedication to advancing medical science, Mthera Pharma seeks to transform the treatment landscape for these challenging diseases.

Pantillogos

Series A in 2021
Pantillogos is a biotech developing next-generation immuno-oncology drugs using immunology, rental and transfer of licenses.

Genedit

Series A in 2021
GenEdit Inc., established in 2016 and headquartered in Berkeley, California, specializes in developing innovative genome editing tools. The company's core technology is CRISPR/Cas9, which enables precise therapeutic gene editing. GenEdit has further advanced this field by creating the NanoGalaxy™ platform, a proprietary non-viral delivery system that efficiently transports CRISPR/Cas9 to target tissues, overcoming previous delivery challenges. This platform systematically screens a library of nanoparticles to ensure safer and more effective delivery, making therapeutic gene editing easier, faster, and more accurate than traditional methods. GenEdit's ultimate goal is to facilitate the cure of previously incurable genetic diseases by providing physicians with powerful tools for gene therapy.

Tomocube

Series C in 2021
Tomocube designs and manufactures 3D optical microscopes that use holotomography to capture non-invasive, dye-free, real-time images of living cells and tissues. Its product line includes HT-1, HT-2, and HT-X1 models, along with software such as TomoAnalysis. The technology enables researchers in cell biology, regenerative medicine, immunology, and 3D biology to study dynamic cellular processes without sample preparation. Founded in 2015 and headquartered in Daejeon, South Korea, Tomocube serves the life science research and diagnostic markets.

Space F

Series A in 2021
Space F is an application industry platform business company that researches and develops cell farming technology.

SeaWith

Series A in 2021
SeaWith is a biotechnology company creating meat alternatives from seaweed, including cell-cultured steak and plant-based substitutes designed to mimic meat texture and flavor. It develops its own culture media from microalgae, aiming to reduce production costs by leveraging the abundance of algae. The company focuses on nutrition and sustainability, providing healthier protein options for consumers seeking alternatives to traditional meat.

Cellaputics Bio

Seed Round in 2021
Cellaputics Bio is a biotechnology company that develops cell therapy for treating degenerative and intractable diseases.

GI Innovation

Series C in 2021
GI Innovation, based in South Korea, specializes in bio-ventures by integrating basic science with translational innovation to develop biologics for global patients. Its strategic focus lies in immuno-oncology and inflammation/immunology diseases, leveraging the GI-SMART platform technology to efficiently optimize multi-targeting fusion protein therapeutics.

Newracle Genetics

Series B in 2021
Newracle Genetics is a bio venture company that develops gene therapy products for neurological diseases.

iN Therapeutics

Series A in 2021
iN Therapeutics is a biotechnology company focused on developing novel therapies for patients with intractable neurological disorders. Its drug development platform concentrates on Nav1.7 non-narcotic analgesics, hearing loss treatments, and brain disease therapeutics, aiming to provide pharmaceutical and biotech industries access to innovative central nervous system disease drugs.

PharmCADD

Series B in 2021
PharmCADD is a developer of an advanced drug development platform that integrates artificial intelligence, molecular dynamics simulation, quantum calculations, and protein structure prediction algorithms to enhance the drug discovery process. The company's key products include Pharmulator, a comprehensive platform designed to streamline drug discovery through five essential modules, which encompass protein and RNA 3D structure prediction, drug generation, virtual screening, quantum calculations, and toxicity prediction. This multifaceted approach aims to identify and generate drug candidates with improved efficacy. Additionally, PharmCADD offers PharmVAC, a specialized vaccine development platform that assists users in designing, analyzing, and visualizing RNA sequences for vaccine candidates, thereby optimizing the development process. Through these innovative tools, PharmCADD addresses the complexities of drug design and aims to accelerate the identification of effective therapies.

Mthera Pharma

Series A in 2021
Mthera Pharma is a biopharmaceutical research and development company focused on creating innovative therapies for complex diseases. The company is working on a pre-clinical drug that aims to enhance the translation of cutting-edge scientific discoveries into effective precision medicine. Mthera Pharma's lead compounds are designed to address multiple targets, enabling healthcare professionals to better manage conditions such as Parkinson's disease and dementia. Through its dedication to advancing medical science, Mthera Pharma seeks to transform the treatment landscape for these challenging diseases.

Master Meditech

Series A in 2021
Master Meditech Inc. is a biotechnology company based in Seoul, South Korea, specializing in the development of new pharmaceuticals through protein structure identification and medicinal chemistry. Established in 2019, the company focuses on leveraging advanced scientific techniques to discover innovative drug candidates, aiming to address various medical needs. With a commitment to enhancing therapeutic options, Master Meditech is positioned at the intersection of technology and healthcare, striving to contribute to advancements in the pharmaceutical industry.

Space F

Seed Round in 2021
Space F is an application industry platform business company that researches and develops cell farming technology.

Novelty Nobility

Series B in 2021
Novelty Nobility Inc. is a private biotech company dedicated to researching novel angiogenesis targets and developing antibody-based therapeutics, particularly in the fields of ophthalmology and oncology. The company has identified Stem Cell Factor (SCF) and c-KIT as significant angiogenesis targets, which are linked to the proliferation and survival of hematopoietic stem cells. By focusing on the anti-SCF/c-KIT pathway, Novelty Nobility aims to address the unmet medical needs associated with existing anti-VEGF treatments, specifically regarding efficacy and long-term safety. The company is actively engaged in developing therapeutic antibodies and antibody-drug conjugates to combat drug resistance and the negative effects of aberrant blood vessel growth in conditions such as retinal diseases and solid tumors. Their lead candidate, NN2101, a full-human monoclonal antibody, is currently in preclinical development and is supported by strong patent protection in the United States and South Korea.

Idience

Series A in 2021
Idience is a drug development company focused on creating and commercializing innovative treatments for cancer. The company specializes in developing potent inhibitors that disrupt the repair of DNA single-strand breaks, leading to increased double-stranded breaks, which can induce synthetic lethality in cancer cells. This approach allows for targeted therapy against multiple solid tumors, both as a standalone treatment and in combination with other anti-cancer agents. Additionally, Idience employs advanced artificial intelligence to enhance medical imaging by automatically detecting and classifying various disorders across multiple imaging modalities, providing structured reports that improve diagnostic accuracy. Through these initiatives, Idience aims to drive significant advancements in cancer treatment and patient care.

Primoris Therapeutics

Seed Round in 2021
Primoris Therapeutics is a medical research and development center.

Elgen Therapeutics

Seed Round in 2021
Elgen Therapeutics develops an anti-cancer therapy platform. The company's platform creates drugs based on a new epigenetic target and the discovery of a new E3 ligase ligand, allowing medical professionals to find treatment for cancer.

Vaxcell Bio

Post in 2021
Vaxcell Bio Therapeutics is a biopharmaceutical company focused on developing innovative therapies for cancer treatment. The firm specializes in creating cell-based and protein-based immunotherapeutics aimed at enhancing the immune system's ability to fight cancer. By leveraging advanced biotechnological methods, Vaxcell Bio is dedicated to addressing unmet medical needs in oncology through its pipeline of anti-cancer drugs and other novel therapeutic solutions.

CURAUM

Series A in 2021
Founded in 2017, CURAUM specializes in developing and selling oral care and sleep-related healthcare products. Its key offerings include Clium Cleaner for dental device cleaning, Clium S-Guard for managing obstructive sleep apnea and snoring, and the Clium System for personalized chronic sleeping disorder management.

JD Bioscience

Series B in 2021
JD Bioscience is a drug development company focused on creating medical research solutions for metabolic disorders. The company specializes in developing small-molecule therapeutics designed to address metabolic complications associated with hard-to-cure diseases. By employing a novel mechanism that efficiently inhibits biogenesis in peripheral white adipose tissues, JD Bioscience aims to provide effective treatment options for obesity and various metabolic diseases.

Revosketch

Series B in 2021
RevoSkectch is a molecular diagnostics company focused on developing digital PCR platform with unique spin partitioning technology. revoskectch is to provide the simplest and affordable digital PCR solutions to life science industry.

MirimGENE

Venture Round in 2020
MirimGene is a biotechnology company focused on developing innovative drugs aimed at treating intractable infections and immune disorders. The company specializes in personalized precision medicine, targeting a novel endogenous immune activation factor network to create effective treatments for infectious diseases that currently have no available therapies and high mortality rates. By addressing intractable immune diseases resistant to existing medications, MirimGene enables healthcare providers to offer solutions for patients who have limited or no treatment options.

Paprika Care

Seed Round in 2020
Paprika Care is a developer of a mobile application designed to assist health-conscious individuals in managing their medication. The application serves as a tracker, reminding users to take their medication on time while also allowing them to monitor their progress and gain insights about their prescriptions. Additionally, Paprika Care's platform enables families and healthcare professionals to remotely oversee the medication intake of their loved ones or patients, fostering better adherence to treatment plans. By combining functionality with user-friendly features, Paprika Care aims to enhance medication management and improve overall health outcomes.

PharmCADD

Series A in 2020
PharmCADD is a developer of an advanced drug development platform that integrates artificial intelligence, molecular dynamics simulation, quantum calculations, and protein structure prediction algorithms to enhance the drug discovery process. The company's key products include Pharmulator, a comprehensive platform designed to streamline drug discovery through five essential modules, which encompass protein and RNA 3D structure prediction, drug generation, virtual screening, quantum calculations, and toxicity prediction. This multifaceted approach aims to identify and generate drug candidates with improved efficacy. Additionally, PharmCADD offers PharmVAC, a specialized vaccine development platform that assists users in designing, analyzing, and visualizing RNA sequences for vaccine candidates, thereby optimizing the development process. Through these innovative tools, PharmCADD addresses the complexities of drug design and aims to accelerate the identification of effective therapies.

ROKIT Healthcare

Series C in 2020
ROKIT Healthcare specializes in advanced medical technologies, focusing on hyper-personalized organ regeneration solutions. They employ artificial intelligence and 3D bioprinting to regenerate skin and cartilage organs for patients through surgical procedures.

Autotac Bio

Series B in 2020
AUTOTAC Bio is a drug development company focused on creating innovative therapeutics through its proprietary protein target decomposition technology. The company aims to address a range of medical challenges by developing treatments for various rare and incurable diseases, including cancers, degenerative brain diseases, amyloid diseases, autoimmunity, and viral infections such as coronavirus. By leveraging autophagy-based mechanisms, AUTOTAC Bio enables pharmaceutical companies to enhance patient health and improve treatment outcomes for conditions that currently lack effective therapies.

Mthera Pharma

Angel Round in 2020
Mthera Pharma is a biopharmaceutical research and development company focused on creating innovative therapies for complex diseases. The company is working on a pre-clinical drug that aims to enhance the translation of cutting-edge scientific discoveries into effective precision medicine. Mthera Pharma's lead compounds are designed to address multiple targets, enabling healthcare professionals to better manage conditions such as Parkinson's disease and dementia. Through its dedication to advancing medical science, Mthera Pharma seeks to transform the treatment landscape for these challenging diseases.

Am Sciences

Series B in 2020
AM Sciences is a drug development company focused on creating therapeutic compounds for the treatment of Hepatitis B and liver fibrosis. The company specializes in developing AMS-I series compounds that act as capsid formation inhibitors. These compounds have demonstrated the potential to significantly enhance the functional cure rates for individuals suffering from chronic Hepatitis B, thereby helping patients alleviate symptoms and prevent disease progression. Through its innovative research and development efforts, AM Sciences aims to provide effective treatments for those affected by these serious liver conditions.

CSK

Venture Round in 2020
CSK Inc. is a manufacturer specializing in products for the semiconductor and LCD industries, with operations in Asia, America, and globally. Founded in 1997 and headquartered in Yongin, South Korea, the company develops a range of solutions including plasma and wet scrubbers, thermal and wet scrubbers, and burn and wet combination scrubbers designed to purify harmful gases generated during semiconductor manufacturing. Additionally, CSK provides precursor delivery systems aimed at waste gas abatement. The company also serves the South Korean markets for display, solar, and LED technologies, positioning itself as a key supplier of exhaust management systems. As of August 2016, CSK operates as a subsidiary of Atlas Copco AB.

Huons Global

Series C in 2020
Huons Global Co is a holding and pharmaceutical company dedicated to providing medical solutions for human health. Established in 1965, the company has a long history of manufacturing high-quality finished products, including Korea's first local anesthetics and plastic ampoule injections. Huons Global operates through three primary divisions: pharmaceuticals, medical devices, and cosmetics. The pharmaceutical division focuses on the production of ethical drugs, while the medical devices division develops equipment for the safe preparation of platelet-poor plasma and platelet concentrate from blood samples. Additionally, the company offers a range of cosmetic products, including cleansers, creams, and sunscreens. With a commitment to stringent quality control and ongoing research and development, Huons Global exports its pharmaceutical products to approximately 30 countries across North and South America, Europe, Japan, Asia, and Africa.

Sugentech

Post in 2020
Sugentech Incorporated is an in-vitro diagnostic company based in Daejeon, South Korea, specializing in personal point-of-care testing products and personalized diagnosis solutions. Founded in 2011, the company focuses on developing innovative healthcare technologies by integrating biotechnology, information technology, and nanotechnology. Sugentech's product offerings include laboratory tests such as immunoblot processors and molecular diagnostics systems, as well as self-diagnostic home testing kits. Their portfolio features tests for various analytes, including C-reactive protein, procalcitonin, and troponin I, along with personal care tests like digital ovulation and pregnancy tests. Formerly known as Accugen Healthcare, Sugentech changed its name in 2013 to reflect its commitment to pioneering advancements in health diagnostics.

Medipixel

Series A in 2019
Medipixel, Inc. is a South Korean MedTech startup founded in 2017, specializing in artificial intelligence-based diagnostic software and semi-autonomous robotic systems for lung cancer and cardiac interventions. The company is comprised of a team of AI experts in computer vision, deep learning, and reinforcement learning, collaborating with top healthcare professionals, including those at Seoul Asan Medical Center, to enhance disease diagnosis and surgical procedures. Medipixel offers three primary solutions for intervention surgeons: an AI-based diagnosis tool that assists in identifying lesions during coronary angiography, a guide and planning solution that visualizes coronary arteries to facilitate guidewire manipulation, and an automated navigation engine that directs robotic units through arteries with real-time commands. These innovations aim to improve surgical outcomes and patient safety by reducing reliance on contrast agents and enhancing the precision of interventions.

Curiox Biosystems

Series B in 2019
Curiox Biosystems Pte. Ltd. is a bioinstrumentation company that specializes in the development and commercialization of innovative assay platforms aimed at advancing the life sciences, drug discovery, and diagnostics. Established in 2007 and headquartered in Singapore, Curiox offers a range of products designed to enhance the efficiency and automation of bioassays, including DropArray microplates for miniaturized assays and Laminar Wash technology for automated cell processing. Its product lineup includes various washing stations, microplates, fluids, and accessories tailored for applications such as bead-based immunoassays, suspension cell assays, high-content assays, and iPS cell research. Leveraging expertise in surface chemistry and engineering, Curiox is committed to overcoming challenges in life science research through improved automation and reproducibility.

Alodokter

Series C in 2019
Alodokter is a digital health platform that offers an end-to-end solution for patients, including telemedicine and access to qualified Indonesian doctors, along with credible health information, supportive communities, and comprehensive reference materials on health subjects; the service also provides doctor appointment booking, guidance on illness and treatment, and healthy living resources to help users make informed health decisions.

MDimune

Series B in 2019
MDimune Inc. is a South Korean therapeutics company focused on developing innovative drug delivery systems. Founded in 2015 and based in Seoul, the company specializes in the creation of cancer therapeutics using immune cell-derived and stem cell-derived vesicles. Its research and development efforts encompass a range of therapeutic areas, including personalized cancer treatments, osteoarthritis, chronic obstructive pulmonary disease, and neurodegenerative disorders. MDimune's proprietary platform enables targeted delivery of drugs, allowing for the development of novel therapeutics that enhance treatment efficacy. The company provides its vesicle-based delivery solutions to biotech and pharmaceutical enterprises, thereby facilitating advanced therapeutic options for patients.

HUINNO

Series A in 2019
Founded in 2014, HUINNO is a digital health company headquartered in Boston with offices in New York and Seoul. It develops healthcare devices to monitor vital signs such as blood pressure, heart rate, ECG, and SpO2, offering real-time data analysis via its app and cloud-based ecosystem. The company focuses on improving chronic cardiac disease management through wearable technology and AI-driven analytics.

StemLab

Series B in 2019
StemLab is a South Korean biotechnology company specializing in regenerative medicine. It focuses on developing cell-based therapies using its proprietary cell reprogramming technology, with an initial focus on treating spinal cord injuries and neurodegenerative diseases like ALS. The company aims to create innovative solutions for conditions with limited treatment options.

Hisense Bio

Series B in 2019
Hisense Bio offers treatment for intractable dental diseases. They provide research on original technology for tooth development and dentin regeneration. They developed physiological dentin regeneration technology and periodontal ligament regeneration technology based on basic dental research . They offer treatment of intractable dental diseases such as tooth decay, dental hypersensitivity, tooth decay, dental caries, and periodontal disease.

CytoDx

Seed Round in 2019
CytoDx is a bio-venture company focused on advancing cancer diagnosis, prediction, and treatment through innovative technology. The company specializes in developing a liquid biopsy platform that isolates and cultures target cells from blood samples. By analyzing genetic material, including DNA from cancer cells found in body fluids such as blood or urine, CytoDx enables early detection of various cancers. Additionally, the company is working on an automated system for precise diagnosis and life cycle monitoring technology aimed at improving cancer management and overcoming challenges associated with the disease.

Tomocube

Series C in 2019
Tomocube designs and manufactures 3D optical microscopes that use holotomography to capture non-invasive, dye-free, real-time images of living cells and tissues. Its product line includes HT-1, HT-2, and HT-X1 models, along with software such as TomoAnalysis. The technology enables researchers in cell biology, regenerative medicine, immunology, and 3D biology to study dynamic cellular processes without sample preparation. Founded in 2015 and headquartered in Daejeon, South Korea, Tomocube serves the life science research and diagnostic markets.

T&R Biofab

Post in 2019
T&R Biofab, established in 2013 and headquartered in Siheung, South Korea, is a biotechnology company specializing in the development of medical devices for transplantation and tissue regeneration. The company focuses on orthopedics, plastic surgery, and dentistry, offering products such as craniomaxillofacial meshes, dental meshes, and patient-specific implants. T&R Biofab utilizes innovative 3D printing technology to manufacture bioresorbable scaffolds that aid in the regeneration and reconstruction of tissues and organs.

Jeisys Medical

Post in 2019
Jeisys Medical, established in 2001 and headquartered in Seoul, South Korea, specializes in designing, developing, and manufacturing medical devices for various healthcare professionals, including plastic surgeons, dermatologists, and physicians. The company's portfolio spans across multiple treatment areas such as fat reduction, skin tightening, rejuvenation, and removal of unwanted pigments, tattoos, and acne. Notable products include LIPOcel, ULTRAcel Q+, and AcGen, marketed under brands like LIPOcel, ULTRAcel, and AcGen. Jeisys Medical distributes its products globally through a network of distributors.

Genomictree

Post in 2019
Genomictree, Inc. is a molecular diagnostics company focused on epigenomic biomarker-based technologies. The company develops innovative solutions aimed at addressing unmet needs within the healthcare market. By leveraging advancements in molecular diagnostics, Genomictree strives to enhance disease detection and management, ultimately improving patient outcomes.

Noul

Venture Round in 2019
Noul is a healthcare technology company that develops innovative diagnostic solutions to tackle chronic and systemic health issues globally. Its flagship product, miLab, is an automated device that combines sample preparation and artificial intelligence-based diagnostics into a single workflow, integrating computer vision AI, biotechnology, hardware, and software engineering. Noul aims to enhance human health by contributing to the eradication of infectious and non-infectious diseases.

ViGenCell

Venture Round in 2019
ViGenCell is a medical company focused on developing immune cell therapy products. The company is dedicated to improving the quality of life and extending the life expectancy of patients with incurable diseases through its innovative therapies. By leveraging advanced technologies in immune cell manipulation and treatment, ViGenCell aims to provide effective solutions for challenging health conditions that currently lack adequate treatment options.

Genoplan

Series B in 2018
Genoplan is a company focused on democratizing healthcare through the application of population genomics and advanced analytics. It provides a personal genetic testing solution that includes a DNA testing kit for analyzing users' saliva. This analysis generates comprehensive reports that offer insights into genetic predispositions, enabling individuals to make informed lifestyle choices regarding diet, fitness, and personal care. By making genomics more accessible, Genoplan aims to foster a deeper understanding of personal health and contribute to the evolution of precision medicine, ultimately empowering individuals to take charge of their well-being.

SCM Lifescience

Series C in 2018
SCM Lifescience, founded in 2014, focuses on the research and development of innovative treatment options for challenging diseases. The company utilizes proprietary technologies for stem cell isolation and production, aiming to create new therapies that offer hope to patients and contribute to overall human welfare. Based in South Korea, SCM Lifescience is also involved in developing medicinal products and hair care solutions, leveraging its expertise in stem cell applications to address various health-related needs.

Carelabs

Venture Round in 2018
Carelabs operates as a digital health company, providing accessible medical services and reliable health information through its platforms.

Ensol Biosciences

Series C in 2018
Ensol Biosciences Inc. is a biopharmaceutical company based in Daejeon, South Korea, specializing in the development of innovative therapies for serious conditions with limited treatment options, including degenerative disc disease, osteoarthritis, various cancers, Alzheimer's dementia, and type 1 diabetes. The company's drug pipeline features several candidates in clinical trials, such as Peniel 2000 for degenerative disc disease and Engedi 1000 for osteoarthritis. Additionally, it is advancing treatments like Charis 1000 for triple negative breast cancer and Moriah 1000 for Alzheimer's disease. Ensol Biosciences also provides contract drug development services, encompassing chemistry, manufacturing, and controls, alongside its Knowledge-based In Silico Drug Discovery platform for identifying new therapeutic candidates. Founded in 2001 and previously known as Ensoltek Co., Ltd., Ensol Biosciences is committed to addressing unmet medical needs through its research and development initiatives.

3D MediVision

Series B in 2018
3D MediVision develops, manufactures, and sells 3D visualization and live-casting systems for surgery. Its product line includes 3D and 2D cameras, recorders, monitors, and ultrasound systems, and it offers SURGFLIX, a surgical content-sharing platform, and VeterFlix, a veterinary training platform. The imaging system can be mounted on surgical microscopes to convert the ocular view into a digital, multi-dimensional image that can be streamed or recorded for educational use. The company distributes its products through authorized distributors in India, Spain, Mexico, and China. Founded in 2011, it is based in Seoul, South Korea.

Y-Biologics

Series C in 2018
Y-Biologics Inc. is a biotechnology company based in Daejeon, South Korea, specializing in the discovery and development of novel antibody therapeutics, particularly in the field of immuno-oncology. Established in 2007, the company has developed a bispecific antibody platform technology known as AliCE, which maintains the structural integrity of the parental antibody, ensuring high binding affinity to cancer antigens. Additionally, Y-Biologics has created the Y-max ABL, a unique library of human antibodies, which supports its research and development efforts. The company is recognized for its contributions to the global immuno-chemotherapeutic drug market and also offers contract research services, aiming to advance its position within the biotechnology sector.

WSG

Series B in 2018
WSG is a manufacturer and supplier specializing in precision-engineered flow components designed for ultra-high-purity applications. The company develops automated and fully integrated welded tube production systems, serving a diverse range of sectors including semiconductors, LCD/OLED displays, microelectronics, biotechnology, life sciences, and pharmaceuticals. WSG focuses on providing clients with vertically integrated manufacturing solutions, emphasizing cost efficiency and high precision in its offerings.

Celemedi

Seed Round in 2018
Celemedi is a technology-based drug development company that develops immune anti-cancer drugs.

Cellid

Venture Round in 2018
Cellid, Inc. is a bioventure company based in Seoul, South Korea, focused on the research and development of immunotherapeutic vaccines for cancer and infectious diseases. The company is advancing several vaccine candidates, including BVAC-C for cervical, head and neck cancers associated with human papilloma virus, BVAC-B for gastric, ovarian, lung, and pancreatic cancers targeting the HER-2/neu antigen, and BVAC-P for prostate and urinary tract cancers utilizing PAP/PSMA antigens. Additionally, Cellid is developing BVAC-M for melanoma and BVAC-Neo, a customized immunotherapeutic vaccine designed from a patient's own cells. Founded in 2006, Cellid aims to create personalized treatment options that leverage the patient's immune system to combat various types of cancer.

Mediogen

Series C in 2018
Mediogen is a life science company focused on the research and development of probiotic medicinal products. It specializes in supplying probiotic raw materials for use in functional foods, general food products, and cosmetics. Utilizing patented coating technology, Mediogen aims to enhance the effectiveness of its probiotics, thereby promoting healthier lifestyles for consumers. The company's commitment to innovation in the probiotic sector positions it as a significant player in the life sciences industry.

Live Cell Instrument

Series A in 2018
Live Cell Instrument designs, manufactures, and supplies advanced imaging systems, microscopes, scientific instruments, and laboratory consumables. Its products include automated imaging systems, microscope incubators, magnetic imaging chambers, heating systems, and LED excitation systems, facilitating modern research.

42Maru

Debt Financing in 2017
42Maru, Inc. is a South Korean technology company established in 2015, specializing in the development of advanced search engine technology designed for artificial intelligence applications. The firm focuses on creating a deep learning-based question-answering system that accurately interprets user intent and provides precise answers in real-time. Its technology encompasses various domains, including information retrieval, machine reading comprehension, and natural language processing, making it applicable across multiple sectors such as smart speakers, connected cars, chatbots, and home automation devices. 42Maru stands out in the market due to its high accuracy, efficient knowledge base expansion, and low operational costs. The company aims to penetrate the consumer market through strategic B2B2C alliances while supporting multiple languages for global expansion. With a team of experts led by a CEO with over 20 years of industry experience, 42Maru has formed partnerships with major telecommunications companies and financial institutions, positioning itself at the forefront of the emerging AI-driven search paradigm.

CURAUM

Founded in 2017, CURAUM specializes in developing and selling oral care and sleep-related healthcare products. Its key offerings include Clium Cleaner for dental device cleaning, Clium S-Guard for managing obstructive sleep apnea and snoring, and the Clium System for personalized chronic sleeping disorder management.

Tiernes

Tiernes is a dental practice that focuses on digital, clear orthodontic treatments. It operates a digital dentistry platform, offering a range of products such as aligner systems, orthodontic mini screws, and other instruments designed to make dental procedures more comfortable for patients.

NeuroXT

NeuroXT is a technology company specializing in the development of software products for precision diagnosis in healthcare. Their primary offerings include NEXT-ATN, NEXT-ALZ-CDx, and NEXT-S, which use magnetic resonance imaging (MRI) to analyze and predict molecular pathology values. This enables healthcare professionals to determine the suitability of specific treatments or drugs for patients with degenerative brain diseases, thereby enhancing precision and personalization in care.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.